newsfilter
← Latest News
Business Wire·

Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes

1,000 participants enrolled across two studies, and six sites Studies will evaluate clinical effectiveness beyond 6 months, impact on medication use and healthcare utilization Better Therapeutics, Inc.